Cargando…

Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System

BACKGROUND: Premature clopidogrel discontinuation after drug‐eluting stent placement is associated with adverse outcomes. Little is known about patient and hospital factors associated with premature discontinuation or whether less variation in premature discontinuation exists in integrated health ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigen, Rebecca, Maddox, Thomas M., O'Donnell, Colin I., Grunwald, Gary K., Bhatt, Deepak L., Tsai, Thomas T., Rumsfeld, John S., Ho, P. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889159/
https://www.ncbi.nlm.nih.gov/pubmed/27151513
http://dx.doi.org/10.1161/JAHA.114.001376
_version_ 1782434955775705088
author Vigen, Rebecca
Maddox, Thomas M.
O'Donnell, Colin I.
Grunwald, Gary K.
Bhatt, Deepak L.
Tsai, Thomas T.
Rumsfeld, John S.
Ho, P. Michael
author_facet Vigen, Rebecca
Maddox, Thomas M.
O'Donnell, Colin I.
Grunwald, Gary K.
Bhatt, Deepak L.
Tsai, Thomas T.
Rumsfeld, John S.
Ho, P. Michael
author_sort Vigen, Rebecca
collection PubMed
description BACKGROUND: Premature clopidogrel discontinuation after drug‐eluting stent placement is associated with adverse outcomes. Little is known about patient and hospital factors associated with premature discontinuation or whether less variation in premature discontinuation exists in integrated health care systems such as the Veterans Affairs (VA). METHODS AND RESULTS: We evaluated the frequency of premature clopidogrel discontinuation, defined as a gap between clopidogrel refills of ≥90 days during the first 6 months of treatment, among 12 707 patients who received drug‐eluting stents in VA hospitals between 2008 and 2010. We evaluated the association between premature discontinuation and all‐cause mortality and/or acute myocardial infarction, variation in the proportion of premature discontinuation among hospitals, the patient and hospital characteristics associated with premature discontinuation, and the extent to which unexplained hospital characteristics contribute to premature discontinuation. Of the patients, 963 (7.6%) discontinued clopidogrel prematurely. Premature discontinuation was associated with acute myocardial infarction and all‐cause mortality (hazard ratio 1.65, 95% CI 1.37–1.99, P<0.001). The proportion of patients with premature discontinuation varied across hospitals from 0% to 16.5% (P<0.001). We found a median of 24% greater odds of patients with identical covariates with premature discontinuation at one randomly selected hospital compared with another (median odds ratio 1.24, 95% CI 1.17–1.44). Patient factors associated with premature discontinuation included lack of cardiology follow‐up within 30 days of discharge and smaller initial clopidogrel fill. CONCLUSION: One in 13 patients prematurely discontinued clopidogrel, and variation in discontinuation across hospitals was observed. Patient factors were associated with premature discontinuation that may represent targets for quality improvement.
format Online
Article
Text
id pubmed-4889159
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48891592016-06-09 Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System Vigen, Rebecca Maddox, Thomas M. O'Donnell, Colin I. Grunwald, Gary K. Bhatt, Deepak L. Tsai, Thomas T. Rumsfeld, John S. Ho, P. Michael J Am Heart Assoc Original Research BACKGROUND: Premature clopidogrel discontinuation after drug‐eluting stent placement is associated with adverse outcomes. Little is known about patient and hospital factors associated with premature discontinuation or whether less variation in premature discontinuation exists in integrated health care systems such as the Veterans Affairs (VA). METHODS AND RESULTS: We evaluated the frequency of premature clopidogrel discontinuation, defined as a gap between clopidogrel refills of ≥90 days during the first 6 months of treatment, among 12 707 patients who received drug‐eluting stents in VA hospitals between 2008 and 2010. We evaluated the association between premature discontinuation and all‐cause mortality and/or acute myocardial infarction, variation in the proportion of premature discontinuation among hospitals, the patient and hospital characteristics associated with premature discontinuation, and the extent to which unexplained hospital characteristics contribute to premature discontinuation. Of the patients, 963 (7.6%) discontinued clopidogrel prematurely. Premature discontinuation was associated with acute myocardial infarction and all‐cause mortality (hazard ratio 1.65, 95% CI 1.37–1.99, P<0.001). The proportion of patients with premature discontinuation varied across hospitals from 0% to 16.5% (P<0.001). We found a median of 24% greater odds of patients with identical covariates with premature discontinuation at one randomly selected hospital compared with another (median odds ratio 1.24, 95% CI 1.17–1.44). Patient factors associated with premature discontinuation included lack of cardiology follow‐up within 30 days of discharge and smaller initial clopidogrel fill. CONCLUSION: One in 13 patients prematurely discontinued clopidogrel, and variation in discontinuation across hospitals was observed. Patient factors were associated with premature discontinuation that may represent targets for quality improvement. John Wiley and Sons Inc. 2016-05-05 /pmc/articles/PMC4889159/ /pubmed/27151513 http://dx.doi.org/10.1161/JAHA.114.001376 Text en © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Vigen, Rebecca
Maddox, Thomas M.
O'Donnell, Colin I.
Grunwald, Gary K.
Bhatt, Deepak L.
Tsai, Thomas T.
Rumsfeld, John S.
Ho, P. Michael
Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
title Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
title_full Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
title_fullStr Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
title_full_unstemmed Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
title_short Hospital Variation in Premature Clopidogrel Discontinuation After Drug‐Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System
title_sort hospital variation in premature clopidogrel discontinuation after drug‐eluting stent placement in the veterans affairs (va) healthcare system
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889159/
https://www.ncbi.nlm.nih.gov/pubmed/27151513
http://dx.doi.org/10.1161/JAHA.114.001376
work_keys_str_mv AT vigenrebecca hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT maddoxthomasm hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT odonnellcolini hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT grunwaldgaryk hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT bhattdeepakl hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT tsaithomast hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT rumsfeldjohns hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem
AT hopmichael hospitalvariationinprematureclopidogreldiscontinuationafterdrugelutingstentplacementintheveteransaffairsvahealthcaresystem